AHCCCS
Pharmacy and Therapeutics Committee Meeting Minutes
August 16, 2016
12:00PM- 4:00 PM
701 E. Jefferson Phoenix, AZ  85034- Gold Room- 3rd Floor

Members Present:
Johanna Kowalik
Robert Marotz
Shawn McMahon
James Hargrave
Lydia Nesemann
Berkley Olvera
Cindy Komar
Gloria Abril
Otto Uhrik
Kathleen Bryant
Suzanne Campbell
Mohamad Ramadan
Stephen Chakmakian
Dan Lindell

AHCCCS Staff:
Sara Salek
Robin Davis
Laura Raymond

Magellan Medicaid Admin:
Doug Brown
Sarah Martinez

Members via teleconference:
Suzi Berman
Olivia Young

Members Absent: None
WELCOME AND INTRODUCTIONS: SARA SALEK, M.D., CHIEF MEDICAL OFFICER, AHCCCS

1. Dr. Sara Salek called the meeting to order at 12:00 PM and welcomed committee members, staff, and guest speakers.

2. 5-17-16 P&T Minutes Review and vote
   a. Motion made by Kathleen Bryant to approve May 2016 meeting minutes
   b. Motion seconded by Dr. Chakmakian
   c. All committee members voted in favor of approving the minutes
   d. No committee members opposed
   e. No committee member abstained

3. P&T Operational Policy Review and Vote
   a. Motion made by Lydia Nesemann to approve P&T Operational Policy
   b. Motion seconded by Dan Lindell
   c. All committee members voted in favor of approving the P&T Operational Policy
   d. No committee members opposed
   e. No committee members abstained

AHCCCS and Behavioral Health Drug Lists

SUPPLEMENTAL REBATE CLASS REVIEW

1. Atypical Antipsychotics (oral and long-acting injectable)
   a. Clinical review: Sarah Martinez: Provider Synergies
   b. Pharma Testimony Oral:
      i. Amy Everitt: Sunovion: Latuda
      ii. Kristin Pareja: Otsuka: Rexulti
   c. Pharma Testimony Long-acting Injectables
      i. Kristin Pareja: Otsuka: Abilify Maintena
      ii. Deborah Profant: Alkermes: Aristada
      iii. Laura Litzenberger: Janssen Scientific Affairs: Invega Sustenna & Invega Trinza
   d. Public Testimony:
      i. John Sarris
ii. William Sullivan II
iii. Deni Nordmeyer
iv. Carol Olson
v. Kristina Sabetta
vi. H. Clarke Romans
vii. Elizabeth Kosloff
viii. Joy Green
ix. Thomas Gazda
x. Ron Dominquez

2. Stimulants and Related Agents
   a. Clinical review: Sarah Martinez: Provider Synergies
   b. Pharma Testimony:
      i. Erin Miller: Shire: Vyvanse & Adderall XR
   c. Public Testimony: None

3. Anticoagulants
   a. Clinical review: Sarah Martinez: Provider Synergies
   b. Pharma Testimony
      i. Jon Glover: BMS/Pfizer: Eliquis
      ii. William Oneill: Boehringer-Ingelheim: Pradaxa
      iii. Laura Litzenberger: Janssen Scientific Affairs: Xarelto
   c. Public Testimony
      i. Jan Prasad

4. Pancreatic Enzymes
   a. Clinical review: Sarah Martinez: Provider Synergies
   b. Pharma Testimony: None
   c. Public Testimony: None

5. Epclusa
   a. Clinical review: Sarah Martinez: Provider Synergies
   b. Pharma Testimony
      i. Coleen Fong, Gilead, Epclusa
   c. Public Testimony: None
6. Executive Session – **Closed to the Public**

7. PDL Recommendations (preferred products)
   a. Antipsychotics (atypical)
      i. Grandfathering-yes
         1. Risperidone tablet
         2. Quetiapine tablet
         3. Olanzapine tablet
         4. Risperidone solution
         5. Risperidone ODT
         6. Ziprasidone capsule
         7. Saphris
         8. Olanzapine ODT
         9. Latuda
         10. Clozapine tablet
         11. Clozapine ODT
         12. Abilify tablet
         13. Risperdal Consta
         14. Aristada
         15. Abilify Maintena
         16. Invega Sustenna
         17. Invega Trinza
   b. Stimulants and Related Agents
      i. Grandfathering of Intuniv (Branded) and Concerta (Branded) only
         1. Strattera
         2. Kapvay
         3. Focalin
         4. Focalin XR
         5. Methylin Chewable Tablets
         6. Methylin Solution
         7. Dextroamphetamine Tablet
         8. Dextroamphetamine ER capsule
         9. Amphetamine salt combo
         10. Adderall XR
         11. Guanfacine ER
12. Vyvanse  
13. Daytrana  
14. Metadate CD  
15. Methylphenidate  
16. Methylphenidate ER (Generic Ritalin LA)  
17. Methylphenidate ER (Generic Concerta)  
18. Ritalin LA 10mg  
19. Quillichew ER  
20. Quillivant XR  

c. Anticoagulants  
   i. Grandfathering- No  
      1. Warfarin  
      2. Pradaxa  
      3. Eliquis  
      4. Xarelto  
      5. Lovenox Vial and Syringe  

   b. Pancreatic Enzymes  
   i. Grandfathering- Yes  
      1. Pancrelipase  
      2. Zenpep  
      3. Creon  

e. Taltz  
   i. Will remain non-preferred until review with Cytokine and CAM antagonist class in November.  (Available through PA process)  

f. Hepatitis C Agents  
   i. Preferred  
      1. Epclusa (Genotype 2 and 3 only)  
      2. Technivie  
      3. Viekira Pak  
      4. Zepatier  
      5. Harvoni  
   ii. Non Preferred
BH DRUG LIST- SARA SALEK

1. Options for Drug List Management
   a. Two separate drug lists are currently posted: The AHCCCS Drug List and the Behavioral Health Drug List. Committee members were asked if there was a preference to keep the drug lists separate or merge into one document.
      i. Motion by Kathleen Bryant to keep the AHCCCS Drug Lists separate.
      ii. Motion Seconded by Mohamad Ramadan
      iii. All committee members voted in favor of the motion.
      iv. No committee members opposed or abstained.

2. Prior Authorization Criteria Approach
   a. PA criteria will be transitioned to Managed Care Contractors to manage criteria.

FOLLOW UP: SARA SALEK/SUZI BERMAN

1. Oral Oncology Agents Drug List management approach-Sara Salek
   a. During a previous meeting, it was recommended that a subcommittee be formed to manage oral oncology agents. Dr. Salek asked for volunteers for the subcommittee.
      i. Stephen Chakmakian, Cindy Komar and Dan Lindell volunteered to be on the subcommittee.

2. Genvoya PA Status- Sara Salek
   a. During a previous meeting, it was recommended that a subcommittee be formed to manage the HIV drug class. Dr Salek asked for volunteers for the subcommittee.
      i. Dan Lindell, Cindy Komar, and Lydia Nesemann volunteered to be on the subcommittee.

NEW DRUG REVIEWS: NON-SUPPLEMENTAL REBATE CLASS: SARAH MARTINEZ, PROVIDER SYNERGIES

1. The following new drugs were reviewed for the Non-Supplemental Rebate Class
   a. Cabometyx – Cabozantinib
i. Recommendation is to add Cabometyxs to the AHCCCS Drug List with Prior authorization.
   1. Motions by Suzanne Campbell to defer until subcommittee meets for this class
   2. Motion seconded by Kathleen Bryant
      a. 13 members voted in favor of the motion.
      b. No committee members opposed.
      c. 1 committee member abstained.

b. Descovy – Emtricitabine &Tenofovir Alafenamide Fumarate
   i. Recommendation is to add Descovy to the AHCCCS Drug List with prior authorization.
      1. Motion by Mohamad Ramadan to defer until subcommittee meets for this class
      2. Motion seconded by Dan Lindell
         a. All committee members voted in favor of the motion.
         b. No committee members opposed.
         c. No committee members abstained.

c. Odefsey- Emtricitabine, Rilpirvirine & Tenofovir Alafenamide
   i. Recommendation is to add Odefsey to the AHCCCS Drug List with prior authorization
      1. Motion made by Suzanne Campbell to defer until subcommittee meets for this class.
      2. Motion seconded by Kathleen Bryant
         a. All committee members voted in favor of the motion.
         b. No committee members opposed.
         c. No committee members abstained.

d. Veltassa- Patiromer Sobitex Calcium
   i. Recommendation is to add Veltassa to the AHCCCS Drug List with prior authorization.
      1. Motion made by Mohamad Ramadan to add with PA
      2. Motion seconded by Robert Marotz
         a. 2 committee members voted in favor of the motion.
         b. 7 committee members opposed.
         c. 5 committee members abstained.

e. Venclexta- Venetoclax
   i. Recommendation is to add Venclexta to the AHCCCS Drug list with prior authorization
      1. Motion made by Stephen Chakmakian to defer until subcommittee meets for this class
      2. Motion seconded by Suzanne Campbell
         a. All committee members voted in favor of the motion.
         b. No committee members opposed.
c. No committee members abstained.

2. The following new drugs were not reviewed for the Non-Supplemental Rebate Class
   a. Cinquair-Reslizumab
      i. Not reviewed due to being an IV agent
   b. Onzeta Xsail & Zembrace Symtouch-Sumatriptan
      i. Not reviewed due to similar/more cost effective formulations of Sumatriptan being available on the AHCCCS Drug list
   c. Sernivo- Betamethasone Dipropionate
      i. Not reviewed due to similar/more cost effective formulations of Betamethasone Dipropionate being available on the AHCCCS Drug list.
   d. Spritam- Levetiracetam
      i. Not reviewed due to Levetiracetam being generically available on the AHCCCS Drug list
   e. Ultravate Lotion- Halobetasol
      i. Not reviewed due to other formulations of Halobetasol being available on the AHCCCS drug list
   f. Xtampza ER-Oxycodone
      i. All long acting opioid narcotics are scheduled for a class review in October2016.

AGENDA ITEMS FOR OCTOBER 19, 2016 P&T

Drug classes and topics for review at the next P&T Committee include:
   1. Antibiotics, Inhaled:
   2. Cytokine & CAM Antagonists:
   3. Epinephrine Self-Injected:
   4. Growth Hormone:
   5. Long-Acting Narcotic Analgesics
   6. Pill splitting- Dr Chakmakian

NEXT MEETING DATES

2016 Next Meeting Date:
Wednesday, October 19, 2016
2017 Meeting Dates:
To be determined

ADJOURNMENT

The meeting adjourned at 4:27
Minutes recorded by Robin Davis

Suzi Berman
Suzi Berman, RPh
Director of Pharmacy Services
AHCCCS

Date: October 19, 2016